Compare AU
Compare CURE vs. EMMG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and EMMG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | EMMG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 7 |
Median incremental investment | $619.50 | $1,997.66 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $1,624.26 |
Average age group | > 35 | > 35 |
Key Summary
CURE | EMMG | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | EMMG.AX was created on 2019-05-29 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to generate after-fee returns in excess of the MSCI Emerging Markets Index expressed in Australian Dollars over rolling five-year periods. The Fund invests in a portfolio of emerging market shares that is actively managed by Legg Masons wholly-owned equity specialist, Martin Currie |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | BetaShares Martin Currie Em Fund (Managed Fund) (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | China (20.90 %) India (20.69 %) Korea (17.98 %) |
Management fee | 0.45 % | 1 % |
Key Summary
CURE | EMMG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 1 % |
Price | $51.33 | $6.42 |
Size | $36.301 million | $15.591 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 4.24 % | 0.56 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 06/06/2019 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | EMMG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 7 |
Median incremental investment | $619.50 | $1,997.66 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $1,624.26 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | EMMG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | EMMG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |